MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
21895872
PubMed Central
PMC11158343
DOI
10.1111/j.1349-7006.2011.02092.x
Knihovny.cz E-zdroje
- MeSH
- DNA modifikační methylasy genetika metabolismus MeSH
- dospělí MeSH
- enzymy opravy DNA genetika metabolismus MeSH
- glioblastom diagnóza genetika metabolismus mortalita MeSH
- Kaplanův-Meierův odhad MeSH
- lidé středního věku MeSH
- lidé MeSH
- metylace DNA MeSH
- mikro RNA biosyntéza MeSH
- nádorové biomarkery genetika metabolismus MeSH
- nádorové supresorové proteiny genetika metabolismus MeSH
- nádory mozku diagnóza genetika metabolismus mortalita MeSH
- přežití po terapii bez příznaků nemoci MeSH
- prognóza MeSH
- promotorové oblasti (genetika) * MeSH
- retrospektivní studie MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- DNA modifikační methylasy MeSH
- enzymy opravy DNA MeSH
- MGMT protein, human MeSH Prohlížeč
- mikro RNA MeSH
- MIrn181 microRNA, human MeSH Prohlížeč
- MIRN195 microRNA, human MeSH Prohlížeč
- MIRN196 microRNA, human MeSH Prohlížeč
- MIRN21 microRNA, human MeSH Prohlížeč
- nádorové biomarkery MeSH
- nádorové supresorové proteiny MeSH
Glioblastoma multiforme (GBM) is the most frequently occurring primary malignant brain tumor; patients with GBM often have a very poor prognosis and differing responses to treatment. Therefore, it is very important to find new biomarkers that can predict clinical outcomes and help in treatment decisions. MicroRNAs are small, non-coding RNAs that function as post-transcriptional regulators of gene expression and play a key role in the pathogenesis of GBM. In a group of 38 patients with primary GBM, we analyzed the expression of eight microRNAs (miR-21, miR-128a, miR-181c, miR-195, miR-196a, miR-196b, miR-221, and miR-222). In addition, we examined the methylation status of O-6-methylguanine-DNA methyltransferase (MGMT) promoter by high-resolution melting analysis, as this has been shown to be a predictive marker in GBM. MGMT methylation status correlated with progression-free survival (P = 0.0201; log-rank test) as well as with overall survival (P = 0.0054; log-rank test). MiR-195 (P = 0.0124; log-rank test) and miR-196b (P = 0.0492; log-rank test) positively correlated with overall survival. Evaluation of miR-181c in combination with miR-21 predicted time to progression within 6 months of diagnosis with 92% sensitivity and 81% specificity (P < 0.0001). Our data confirmed that the methylation status of MGMT but also miR-21, miR-181c, miR-195, and miR-196b to be associated with survival of GBM patients. Above all, we suggest that the combination of miR-181c and miR-21 could be a very sensitive and specific test to identify patients at high risk of early progression after surgery.
Zobrazit více v PubMed
Schwartzbaum JA, Fisher JL, Aldape KD et al. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006; 2: 494–503; quiz 1 p following 16. PubMed
Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population‐based study. Cancer Res 2004; 64: 6892–9. PubMed
Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–96. PubMed
Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5‐year analysis of the EORTC‐NCIC trial. Lancet Oncol 2009; 10: 459–66. PubMed
Esquela‐Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259–69. PubMed
Sana J, Hajduch M, Michalek J et al. MicroRNAs and glioblastoma: roles in core signaling pathways and potential clinical implications. J Cell Mol Med 2011; 15: 1636–44. PubMed PMC
Novakova J, Slaby O, Vyzula R et al. MicroRNA involvement in glioblastoma pathogenesis. Biochem Biophys Res Commun 2009; 386: 1–5. PubMed
Slaby O, Lakomy R, Fadrus P et al. MicroRNA‐181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma 2010; 57: 264–9. PubMed
Ujifuku K, Mitsutake N, Takakura S et al. miR‐195, miR‐455‐3p and miR‐10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 2010; 296: 241–8. PubMed
Guan Y, Mizoguchi M, Yoshimoto K et al. MiRNA‐196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res 2010; 16: 4289–97. PubMed
Hegi ME, Liu L, Herman JG et al. Correlation of O6‐methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008; 26: 4189–99. PubMed
Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26: 2192–7. PubMed
Sadones J, Michotte A, Veld P et al. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer 2009; 45: 146–53. PubMed
Blanc JL, Wager M, Guilhot J et al. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 2004; 68: 275–83. PubMed
Wojdacz TK, Dobrovic A. Methylation‐sensitive high resolution melting (MS‐HRM): a new approach for sensitive and high‐throughput assessment of methylation. Nucleic Acids Res 2007; 35: e41. PubMed PMC
Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997–1003. PubMed
Eoli M, Menghi F, Bruzzone MG et al. Methylation of O6‐methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res 2007; 13: 2606–13. PubMed
Weller M, Felsberg J, Hartmann C et al. Molecular predictors of progression‐free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743–50. PubMed
Wang X, Wang J, Ma H et al. Downregulation of miR‐195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol 2011; DOI: 10.1007/s12032‐011‐9880‐5 [Epub ahead of print]. PubMed
Xu T, Zhu Y, Xiong Y et al. MicroRNA‐195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009; 50: 113–21. PubMed
Liu L, Chen L, Xu Y et al. microRNA‐195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun 2010; 400: 236–40. PubMed
Soon PS, Tacon LJ, Gill AJ et al. miR‐195 and miR‐483‐5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. Clin Cancer Res 2009; 15: 7684–92. PubMed
Ciafre SA, Galardi S, Mangiola A et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005; 334: 1351–8. PubMed
Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA‐21 targets a network of key tumor‐suppressive pathways in glioblastoma cells. Cancer Res 2008; 68: 8164–72. PubMed
Chen Y, Liu W, Chao T et al. MicroRNA‐21 down‐regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett 2008; 272: 197–205. PubMed
Chan JA, Krichevsky AM, Kosik KS. MicroRNA‐21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029–33. PubMed
Srinivasan S, Patric IR, Somasundaram K. A ten‐microRNA expression signature predicts survival in glioblastoma. PLoS ONE 2011; 6: e17438. PubMed PMC
Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade
MicroRNAs involved in chemo- and radioresistance of high-grade gliomas
Novel classes of non-coding RNAs and cancer